Ziihera's 26.4-Month OS Is Compelling but Comparator Opacity Leaves Incremental Value Unresolved

FDA Approves Ziihera for First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals announced that the U.S. FDA approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA). The approved regimens include Ziihera plus tislelizumab and chemotherapy for all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+), and Ziihera plus chemotherapy for HER2+ IHC 3+ patients. This approval, based on the Phase 3 HERIZON-GEA-01 trial, establishes Ziihera as the first and only bispecific HER2-targeted antibody combined with a PD-1 inhibitor and chemotherapy approved for all HER2+ advanced GEA patients, regardless of PD-L1 status, setting a new standard of care. The trial demonstrated a median overall survival of 26.4 months, the longest reported in this setting.

• The FDA approval of Ziihera marks a significant advancement for HER2+ advanced GEA patients, establishing a new first-line standard of care. Ziihera is now the sole bispecific HER2-targeted antibody approved in combination with a PD-1 inhibitor (tislelizumab) and chemotherapy for all HER2+ GEA patients, irrespective of their PD-L1 status. This broad approval addresses a critical unmet need in a cancer associated with poor outcomes.
• The approval is underpinned by robust data from the Phase 3 HERIZON-GEA-01 trial. Ziihera-containing regimens significantly improved progression-free survival (PFS), reducing the risk of disease progression or death by 35% and extending median PFS to 12.4 months compared to 8.1 months with trastuzumab plus chemotherapy. Furthermore, the Ziihera plus tislelizumab and chemotherapy regimen achieved a median overall survival (OS) of 26.4 months, a statistically significant and clinically meaningful improvement over 19.2 months for the comparator arm, representing the longest median OS reported in this setting.
• Ziihera-containing regimens demonstrated a manageable safety profile consistent with previous studies, with diarrhea being the most common adverse reaction, typically early in onset and managed with prophylaxis and treatment modifications. The drug carries Boxed Warnings for diarrhea and embryo-fetal toxicity. Zanidatamab has previously received three Breakthrough Therapy designations and two Fast Track designations from the FDA for various HER2-expressing cancers, underscoring its therapeutic potential.

The Urgent Need for New HER2+ GEA Treatments

Despite meaningful advances with trastuzumab-based regimens, HER2-positive gastroesophageal adenocarcinoma (GEA) remains a difficult-to-treat malignancy, with median survival for advanced or recurrent disease falling below 15 months. Multiple biological, technical, and clinical factors continue to undermine the durability of HER2-directed therapies, underscoring the urgent need for next-generation treatment strategies.

• HER2 expression loss following targeted therapy: Resistance to trastuzumab is frequently accompanied by loss of HER2 expression. In a cohort of 33 HER2-positive gastric cancer patients with refractory disease, 60.6% exhibited HER2 loss post-treatment, with HER2 3+ overexpression rates declining from 72.7% pre-treatment to 39.4% post-treatment. This dynamic necessitates reassessment of HER2 status at progression to guide subsequent therapeutic decisions.

• Intratumoral HER2 heterogeneity: Spatial heterogeneity of HER2 expression within tumors is both a prognostic factor and a driver of acquired resistance to HER2-directed agents — including trastuzumab, trastuzumab deruxtecan (T-DXd), and disitamab vedotin (RC48). HER2-heterogeneous tumors exhibit distinct intratumoral genetic variation across HER2-positive and HER2-negative regions, complicating both accurate classification and therapeutic targeting.

• PI3K/Akt pathway alterations conferring resistance: PIK3CA mutations (reported in 4–25% of cases) and PTEN inactivation (16–77%) drive constitutive downstream signaling independent of HER2, diminishing the efficacy of upstream HER2-directed therapy. Broader resistance mechanisms also include structural alterations in HER2, dysregulation of downstream effectors, and aberrant cross-talk with other membrane receptors.

• Lack of effective second-line HER2-targeted options (until recently): Prior to the introduction of T-DXd, no anti-HER2 therapy had demonstrated a survival advantage in the second-line setting for HER2-positive gastric cancer, representing a critical therapeutic gap for patients progressing on first-line regimens.

• Technical variability in HER2 testing: Pre-analytical factors — particularly fixative type — significantly affect HER2 positivity rates, with non-standard fixatives (other than 10% neutral buffered formalin) reducing detection accuracy. As the therapeutic landscape expands, precise biomarker characterization and standardized testing conditions become increasingly essential for optimal patient selection.

• Treatment-related toxicity requiring vigilance: T-DXd carries a recognized risk of interstitial lung disease (ILD) or pneumonitis, observed in 13.9% of treated patients (predominantly grade 1–2, with grade 3 in a minority). Although largely low-grade, this toxicity profile demands proactive monitoring and may limit use in vulnerable patient populations.

HERIZON-GEA-01: Ziihera's Pivotal Efficacy and Safety Outcomes

The DESTINY-Gastric04 trial evaluated trastuzumab deruxtecan (6.4 mg/kg) versus ramucirumab plus paclitaxel in HER2-positive gastroesophageal adenocarcinoma. Trastuzumab deruxtecan demonstrated a statistically significant overall survival benefit (median 14.7 vs. 11.4 months; HR 0.70; 95% CI, 0.55–0.90; P=0.004), along with a more favorable progression-free survival (HR 0.74; 95% CI, 0.59–0.92) and a higher confirmed objective response rate (44.3% vs. 29.1%). From a safety standpoint, drug-related adverse events of any grade occurred in 93.0% versus 91.4% of patients, with grade ≥3 events in 50.0% versus 54.1%, respectively. Notably, adjudicated drug-related interstitial lung disease or pneumonitis was observed in 13.9% of patients receiving trastuzumab deruxtecan compared with 1.3% in the comparator arm.

The HLX22 Phase 2 study (NCT04908813) investigated HLX22, a novel anti-HER2 antibody, in combination with HLX02 (a trastuzumab biosimilar) and XELOX chemotherapy at two dose levels (25 mg/kg and 15 mg/kg) versus placebo plus HLX02 and XELOX. At a median follow-up of 14.3 months, IRRC-assessed median PFS was notably prolonged in both HLX22 arms relative to placebo (25 mg/kg: 15.1 vs. 8.2 months, HR 0.5 [95% CI, 0.17–1.27]; 15 mg/kg: not reached vs. 8.2 months, HR 0.1 [95% CI, 0.04–0.52]), though confirmed objective response rates were comparable across all three groups (77.8%, 82.4%, and 88.9%, respectively). Treatment-related adverse events were reported in 100%, 94.1%, and 94.4% of patients in the 25 mg/kg, 15 mg/kg, and placebo groups, with one grade 5 treatment-related adverse event occurring in the placebo group.

A third study evaluated inetetamab combined with the SOX regimen (S-1 plus oxaliplatin) versus trastuzumab plus SOX as first-line therapy. Inetetamab demonstrated a statistically significant improvement in median PFS (8.5 vs. 7.3 months; P=0.046), though the difference in median OS (15.4 vs. 14.3 months; P=0.33) and objective response rate (50% vs. 42%; P=0.63) did not reach statistical significance. The safety profile was broadly consistent between arms; common adverse events included leukopenia, thrombocytopenia, nausea, and vomiting, with grade ≥3 adverse events occurring in 56% of inetetamab-treated patients versus 47% in the trastuzumab group (P=0.63).

Zanidatamab's Expanding Pipeline and Future Potential

Beyond HER2-positive gastroesophageal adenocarcinoma, zanidatamab is being investigated across a broad spectrum of HER2-expressing or HER2-amplified malignancies. These trials span multiple intervention models — from first-in-human dose-escalation studies to disease-specific phase II programmes — reflecting the molecule's potential as a backbone therapy across HER2-driven tumour types.

• HER2-Positive Metastatic Breast Cancer (NCT04224272): A single-arm, two-part phase 2a study evaluating zanidatamab in combination with palbociclib and fulvestrant in patients with hormone receptor-positive, HER2-positive metastatic breast cancer who had previously received HER2-targeted therapies.

• HER2-Positive Breast Cancer — First-Line Setting: An open-label, multicentre phase Ib/II study assessing zanidatamab combined with docetaxel as first-line treatment in patients with unresectable, locally advanced, recurrent, or metastatic HER2-positive breast cancer; Cohort 1 enrolled patients from China and South Korea.

• HER2-Amplified Biliary Tract Cancer (HERIZON-BTC-01; NCT04466891): A global, multicentre, single-arm phase 2b trial of zanidatamab monotherapy in patients with HER2-amplified, unresectable, locally advanced, or metastatic biliary tract cancer who had experienced disease progression on prior gemcitabine-based therapy.

• Broad HER2-Expressing or HER2-Amplified Solid Tumours (NCT02892123): A first-in-human, multicentre phase 1 dose-escalation and expansion trial of zanidatamab monotherapy across a range of solid tumour types — including biliary tract cancer and colorectal cancer — with part 2 specifically excluding breast and gastro-oesophageal cancers to focus on other HER2-driven malignancies.

Ziihera's New Era in HER2+ GEA Treatment

The recent FDA approval of Ziihera-containing regimens for first-line HER2-positive gastroesophageal adenocarcinoma (GEA) marks a significant turning point in the management of this aggressive disease. For years, treatment options for advanced HER2+ GEA have seen limited progress beyond initial trastuzumab efficacy, leaving a substantial unmet need for more effective therapies. This approval introduces a novel therapeutic paradigm, leveraging a bispecific HER2-targeted antibody in combination with a PD-1 inhibitor and chemotherapy.

This multi-pronged approach has demonstrated remarkable clinical outcomes, most notably a median overall survival of 26.4 months in the HERIZON-GEA-01 trial—the longest reported in this challenging setting. This establishes a new benchmark for patient prognosis and offers renewed hope for individuals facing this diagnosis. Strategically, Ziihera's unique position as the first and only such combination approved for all HER2+ GEA patients, irrespective of PD-L1 status, provides a strong competitive advantage and broadens the eligible patient population, including both IHC 3+ and IHC 2+/ISH+ classifications. This validation of dual pathway targeting with chemotherapy could also inspire similar innovative combination strategies across oncology.

However, the path forward is not without considerations.

• The safety profile, particularly the high incidence of diarrhea and grade ≥3 treatment-related adverse events observed in earlier trials, will require careful management to ensure patient tolerability and adherence in real-world settings.

• Furthermore, the landscape of HER2-directed therapies is rapidly evolving. While Ziihera sets a new standard, emerging agents like trastuzumab deruxtecan (T-DXd) are also showing promising efficacy in gastrointestinal malignancies, suggesting future competitive pressures.

• Finally, the inherent challenge of overcoming resistance mechanisms in cancer remains a critical area of ongoing research, implying that even with this breakthrough, continuous innovation will be necessary to sustain long-term patient benefits.

This approval represents a pivotal era in upper GI malignancy management, underscoring the profound impact of integrating novel therapeutic combinations. It highlights the dynamic shifts in treatment strategies and the critical role of ongoing research in tailoring therapies to individual disease profiles.